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1. Introduction 
A low molecular weight, calcium binding protein 
has been located in several hepatomas [l], and puri- 
fied to homogeneity [2]. The tumour calcium-binding 
protein (tumour CaBP) binds 2 calcium atoms/mole- 
cule, has an isoelectric point of 3.9, and is Mr 11 500 
[2]. It cannot be located chemically [l] or immuno- 
electrophoretically [3] in any normal tissue. The 
N-terminus is blocked, and the amino acid composi- 
tion is similar to parvalbumin, a Mr 11 500 calcium- 
binding protein from muscle [2]. However comparison 
with rat parvalbumin shows the two to be different 
(unpublished). 
Calmodulin (CaM) is a larger (M, 16 700) ubiqui- 
tous calcium-binding protein which activates many 
different enzymes, including cyclic nucleotide phos- 
phodiesterase (reviews [4-71). Amino acid sequence 
data show this protein to be highly conserved through- 
out plant and animal evolution, and to belong to the 
troponin C superfamily [ 81, which also includes 
parvalbumin. 
There have been reports that troponin C and par- 
valbumin can substitute for CaM in activation of 
some CaM-dependent enzymes [9,10], although con- 
tamination of these muscle proteins with CaM has 
been suggested [4,11]. This communication demon- 
strates that the tumour CaBP was neither contami- 
nated with CaM nor a fragment of CaM, yet stimulated 
a CaM-dependent enzyme in a calcium-dependent 
manner. 
2. Materials and methods 
Tumour CaBP from rat hepatoma [2], CaM from 
rat testes [ 121, and parvalbumin from rat skeletal 
Ekevier/North-Holland Biomedical Press 
muscle (unpublished) were purified to homogeneity 
(fig.1). Cyclic [3H]guanosine 3’,5’ monophosphate 
(17 Ci/mmol) was from New England Nuclear (Dorval, 
P. Q.), and was purified by AG-IX-8 (BioRad Labs., 
Mississauga, Ont.) chromatography before use. [lz51]- 
Bolton-Hunter reagent (1375 Ci/mmol) was from 
Amersham (Oakville, Ont.). DEAE-Sephacel, 
-+36K 
Fig. 1. Polyacrylamide gel electrophoresis. (A) SDS gel elec- 
trophoresis in 10% gels, 1 mM CaCl, (pH 8.9) of: (1) rat tes- 
ticular calmodulin; (2) rat hepatoma calcium binding protein; 
(3) rat skeletal muscle parvalbumin. The gels were overloaded 
with 50 pg each protein to visualise possible impurities. (B) 
SDS gel electrophoresis in 7.5% gels of 20 fig calmodulin- 
affinity purified phosphodiesterase. Arrows indicate the migra- 
tion of albumin (Mr 67 000), catalase subunit (Mr 60 000), 
ovalbumin (M, 43 000), and lactate dehydrogenase subunit 
(Mr 36 000). 
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Table 1 
Estimate of calmodulin contamination during purification of tumour calcium- 
binding protein 
April 1981 
Fraction Vol. 1251 
(ml) (cpmlml) 
CaMa TCaBPb 
(mg) (mg) 
100 000 x g 
supernatant 850 5 x lo8 (100%) 7.2 (100%) 28.1 (100%) 
pH4 
]65% (NH,),SG,] 125 1 x lo8 (20%) 1.6 (22%) 20.4 (73%) 
DEAE-cellulose 1.5 1 x lo6 (0.2%) n.d. 15.1 (54%) 
Sephadex G-50 12.5 5 x lo5 (0.09%) nd. 9.2c (33%) 
aMeasured by radioimmunoassay [ 141; bmeasured by rocket immunoelectropho- 
resis [3]; Cmeasured as dry weight after lyophilisation; nd., not detectable 
Extract from 350 g tumour was spiked with 5 pg ‘251-labeled calmodulin 
Sephadex G-50, and CNBr-activated Sepharose were 
from Pharmacia (Dorval, P. Q.). Affigel-60 1, Chelex- 
100 and PAGE materials were from BioRad. Trifluo- 
perazine was the gift of Smith, Kline and French 
(Toronto, Ont.). Thin-layer cellulose sheets were 
from Brinkmann (Rexdale, Ont.). All other chemicals 
were of the highest purity available. 
CaM-Sepharose (3 mg CaM/g gel) was prepared 
as in [13], and CaM was iodinated (140 000 cpm/ng) 
using the [ 12’1] Bolton-Hunter reagent [ 141. [ CaM] 
was measured by radioimmunoassay using an anti- 
body raised in this laboratory in sheep. The anti-CaM 
IgG was purified on CaM-Sepharose [ 1.51. Peptide 
maps of the tumour CaBP or CaM were produced by 
treating 1 mg samples of performic acid-oxidised pro- 
teins with TPCK-treated trypsin [ 16,171. The pep- 
B 
Fig.2. Peptide map of (A) tumour calcium-binding protein and (B) calmodulin. Samples (1 mg) of performic acid-oxidised [ 161 pro- 
teins, which had been exhaustively dialysed against 50 mM NH,HCO,, 1 mM EGTA (pH 8.0) were hydrolysed with TPCK-treated 
trypsin. Samples (50 ng) were chromatographed on cellulose thin-layers in n-butanol:pyridine:acetic acid:H,O (50:33:1:40), fol- 
lowed by electrophoresis (11 mA/lOO min) in the second dimension in pyridine:acetic acid:H,O (1:10:89) [ 16,181. The peptides 
were stained with Cd-ninhydrin [33], and tyrosine located by spraying with o-nitroso-p-naphtol [34]. Thick contours were clearly 
visible spots, thin contours were faintly visible, hatched areas were yellow spots, and stippled areas stained for tyrosine. 
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tides were separated in two dimensions on cellulose 
plates [ 181. 
Cyclic GMP phosphodiesterase was purified from 
rat heart by two DEAE-Sephacel steps following the 
procedure for bovine heart [ 191. This enzyme was 
then further purified by CaM affinity chromatography 
[ 131 yielding a major protein band of Mr 53 000 
(fig.1 ; [ 13,191). Enzyme activity was measured by 
direct assay using boronate affinity methods [20]. 
All reagent solutions had <2 JLM calcium by atomic 
absorption spectrometry (Pye Unicam SP 19 1) when 
finally used. Components were treated with Chelex- 
100 ion-exchange resin to reduce the [calcium] to 
this level. Free [calcium] was calculated using the 
computer programme in 1211. Plastic laboratory ware 
was used for all enzyme studies. 
3. Results and discussion 
Before investigating the potential of the tumour 
CaBP to activate a CaM-dependent enzyme, it was 
first necessary to show that the purified protein was 
free of CaM contamination. The high speed super- 
natant of a Morris hepatoma 5 123 homogenate [2] 
was spiked with 5 E.rg 1251-labeled CaM. The tumour 
CaBP was purified [2], and each step assayed for CaM 
and rz51-radioactivity (table 1). The final material 
from Sephadex G-50 had no radioimmunoassayable 
CaM, and the “‘1 content equated to a maximum possi- 
ble contamination of the 9.2 mg tumour CaBP with 
0.07% CaM by weight. This preparation of the tumour 
CaBP was considered essentially free of CaM, and was 
used throughout these studies. 
Besides showing the tumour CaBP to be free of CaM 
contamination, it was also necessary to show that the 
tumour protein was not a fragment of CaM before 
enzyme studies were undertaken. Tryptic peptide maps 
of both rat calcium-bin~ng proteins were produced. 
CaM yielded 13 peptides and the tumour CaBP 
yielded 11 (fig.2). Differential staining with Cd-nin- 
hydrin, and the location of peptides containirlg TUT 
showed that all 11 peptides of the tumour CaBP were 
clearly different from the CaM peptides. This sup- 
ported the suggestion that the tumour CaBP could 
not be a fraglnent of CaM [z]. When a mixture of the 
hydrolysates from the two proteins was mapped the 
entire 24 peptides could be distinguished (not shown). 
Since the tumour CaBP was neither contaminated 
with, nor a fragment of, CaM, its effect on cyck 
nucleotide phosphodiesterase was studied. The CaM 
affinity purified enzyme was, as expected, stimulated 
by CaM (fig3A). Chelation of calcium in the reaction 
mixture with EGTA elim~ated this stimulation. The 
phosphodiesterase was also stimulated in a calcium- 
dependent manner by the smaller tumour CaBP 
(fig.LiA). However -lo-fold more tumour protein 
.E 
“g 60 
Fig.3. The stimulation of c~modulin-dependent cyclic GMP 
phosphodiesterase by tumour calcium-binding protein. The 
assay was performed in 200 ~1 final vol. containing 100 mM 
KCl, 50 mM MgCl,, 50 mM Hepes, 0.2 mM dithiothreitol, 
0.2 mg/ml bovine serum albumin (pH 7.0) and 0.5-S &i 
cyclic [ 3H]GMP (1000-200 cpmjmol). Reaction conditions 
at 37°C were adjusted so that <15% of the substrate was 
hydrolysed. The enzyme (40 ng protein) was incubated for 
5 min (1 nM cyclic GMP) under conditions: (A) of changing 
curium-binding protein concentration; (B) of changing free 
calcium concentration (I mM EGTA) at 1 MM calcium-bind- 
ing protein. (0) Calmodutin; (0) tumour calcium-binding pro- 
tein; (a) parvalbumin. All points are the mean of 210 sepa- 
rate determinations. The SEM was too small to be shown. 
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Fig.4. Inhibition of cyclic GMP phosphodiesterase stimula- 
tion by trifluoperazine. Assay conditions were as in fig.3. (A) 
decreased hydrolysis of cyclic GMP (1 PM) with increased 
concentration of trifluoperazine. (B) Dixon plot [ 351 of 
enzyme activity at 0.5 PM and 5 tiM cyclic GMP. (0,=) Cal- 
modulin; (o,o) tumour calcium-binding protein. 
was required to give the same stimulation as CaM. 
This could not have been due to 10% contamination 
of the tumour protein with CaM (table 1). Parval- 
bumin, of similar size and calcium binding capacity 
as the tumour CaBP was unable to activate the phos- 
phodiesterase ven up to 10 PM confirming [4,11]. 
The free calcium requirement for stimulation of 
cyclic GMP hydrolysis was similar for both CaM and 
the tumour CaBP (fig.3B). 
Trifluoperazine, an antipsychotic agent, binds to 
CaM [22], and inhibits CaM-dependent enzymes 
[5,23,24]. The drug inhibited cyclic nucleotide hydrol- 
ysis whether it was stimulated by CaM or the tumour 
CaBP (figAA). However the Ki for the non-competi- 
tive inhibition by trifluoperazine with the tumour 
protein (20 PM) was double that with CaM (fig.4B). 
Thus a M, 11 500 calcium-binding protein from 
neoplastic liver has the potential to activate a CaM- 
dependent enzyme from normal rat tissue. This pro- 
tein cannot be detected in normal tissue [ 1,3]. 
Another example of a change in normal levels of a 
calcium-binding protein in tumour cells may be the 
increase in CaM described in [25-291. CaM can stim- 
ulate DNA synthesis in quiescent non-neoplastic rat 
liver cells in vitro 1301, and the tumour CaBP can also 
mimic this action of CaM (A. L. Boynton and J. F. 
Whitfield, unpublished). While the function of the 
tumour CaM-like protein is unknown, its presence 
248 
may be linked, along with abnormal CaM levels, to 
perturbed calcium control mechanism, vividly demon- 
strated by the ability of neoplastic cells to grown in 
abnormally low extracellular calcium [3 1,321. 
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